The region’s most experienced transcatheter aortic valve replacement (TAVR) program continues to set records while helping people with malfunctioning aortic valves get back into the life they want.
Lehigh Valley Heart and Vascular Institute recently surpassed 2,000 TAVR procedures, with the program continuing to shine for its great outcomes. TAVR was first approved by the Food and Drug Administration in 2011.
“This milestone really helps illustrate the fact that the heart and vascular institute is the region’s go-to heart health partner,” Ronald Freudenberger, MD, Physician in Chief, Lehigh Valley Heart and Vascular Institute, says. “TAVR procedures give qualifying people a second chance with a minimally invasive procedure that’s extremely effective.”
TAVR is used to treat aortic stenosis, one of the most common heart valve diseases. Aortic stenosis is a narrowing of the heart valve opening. Treatment depends on the severity of the disease. Without treatment it can lead to heart failure and can be fatal.